Feed / PTGX

Protagonist Therapeutics, Inc.

PTGX

Healthcare · 150.52 -2.7% today

Isolated · not yet confirmedMarket checked 25 Aug, 15:55 GMT-4

Jodie situation report

Protagonist Therapeutics, Inc.'s current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 11 directly disclosed connections are confirming.

Company-2.7% todayVolume comparison unavailable
Market group0 of 37 activeBiotechnology · unavailable
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
  • Company opted out of U.S. profit-and-loss sharing with Takeda and is eligible for specified milestone payments including up to $400M plus a $75M enhanced approval milestone.
  • R&D costs rose due to $8.9M in Phase 1 study costs for PN-881 (initiated Q3 2025) plus $6.0M in preclinical/discovery expense, partly offset by lower rusfertide costs.

Invalidation: The isolated read changes if PTGX's group or a disclosed connection begins moving with it.

Watch this read

Who this business touches

The relationships behind PTGX

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

TAKTakeda Pharmaceutical Company LimitedpartnerMay 5, 2026

We discovered rusfertide, advanced it into Phase 3 development, and in early 2024 entered into a co-development and co-commercialization arrangement with Takeda Pharmaceuticals, Inc.

PFEPfizer, Inc.customerFeb 25, 2026

Pfizer, which completed its acquisition of Metsera in 2025, is developing next-generation oral and peptide-based incretin therapies for obesity and related cardiometabolic conditions.

ALTAltimmune, Inc.partnerFeb 25, 2026

Other emerging approaches include dual GLP-1/glucagon receptor agonists, such as survodutide (Boehringer Ingelheim) and pemvidutide (Altimmune).

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 12 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

PTGX is currently a Follower in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.